Diclofenac

Diclofenac

SCHEMBL418230

Cl.O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Diclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 known ✓ P35354 8/20 0.97
PTGS1 known ✓ P23219 2/20 0.97
CXCL8 P10145 4/20 0.97
TTR P02766 3/20 0.97
AKR1B10 O60218 1/20 0.97
UGT1A9 O60656 1/20 0.97
TRPA1 O75762 1/20 0.97
ABCB11 O95342 1/20 0.97
MT-CO2 P00403 1/20 0.97
ALB P02768 1/20 0.97
UGT1A6 P19224 1/20 0.97
UGT1A1 P22309 1/20 0.97
CXCR1 P25024 1/20 0.97
ADRA1A P35348 1/20 0.97
AGTR2 P50052 1/20 0.97
NR1I3 Q14994 1/20 0.97
SLC22A6 Q4U2R8 1/20 0.97
NR1H4 Q96RI1 1/20 0.97
UGT1A7 Q9HAW7 1/20 0.97
UGT1A10 Q9HAW8 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diclofenac SCHEMBL29354260 0.98 PTGS2 (1.00) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL2799 0.98 PTGS2 (1.00) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL996716 0.98 PTGS2 (1.00) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL2216520 0.97 PTGS2 (0.97) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL22370200 0.97 PTGS2 (0.97) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL1178502 0.97 PTGS2 (0.97) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL40785 0.97 PTGS2 (0.97) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL22129258 0.97 PTGS2 (0.97) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL24010 0.97 PTGS2 (0.97) PTGS2CXCL8TTRPTGS1AKR1B10
Diclofenac SCHEMBL4615491 0.97 PTGS2 (0.97) PTGS2CXCL8TTRPTGS1AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015200149-A1 ALL NATURAL ENTERIC SOFT CAPSULES COMPRISING ACTIVE INGREDIENTS BANNER LIFE SCIENCES LLC (US) 2015-12-30 WO claimed
US-20150366814-A1 ALL-NATURAL ENTERIC SOFT CAPSULES COMPRISING ACTIVE INGREDIENTS BIONPHARMA HEALTHCARE LLC 2015-12-24 US claimed
JP-2215720-A None JP disclosed
WO-2021132653-A1 ANTI-POLLUTION MATERIAL 日産化学株式会社 2021-07-01 WO disclosed
WO-2021132668-A1 MATERIAL FOR PROMOTING PENETRATION 日産化学株式会社 2021-07-01 WO disclosed
WO-2021020560-A1 PIGMENT INCLUDING CELLULOSE 日産化学株式会社 2021-02-04 WO disclosed
CN-110545850-A Releasable conjugates QUIAPEG PHARMACEUTICALS AB 2019-12-06 CN disclosed
US-10357467-B2 All-natural enteric soft capsules Patheon Softgels, Inc. (US) 2019-07-23 US disclosed
US-20180271817-A1 ALL-NATURAL ENTERIC SOFT CAPSULES PATHEON SOFTGELS INC (US) 2018-09-27 US disclosed
US-9987240-B2 All-natural enteric soft capsules Patheon Softgels, Inc. (US) 2018-06-05 US disclosed
CN-108024998-A Include the composition of S1P receptor modulators 阿卡制药有限公司 2018-05-11 CN disclosed
WO-2015200149-A1 ALL NATURAL ENTERIC SOFT CAPSULES COMPRISING ACTIVE INGREDIENTS BANNER LIFE SCIENCES LLC (US) 2015-12-30 WO disclosed
US-20150366814-A1 ALL-NATURAL ENTERIC SOFT CAPSULES COMPRISING ACTIVE INGREDIENTS BIONPHARMA HEALTHCARE LLC 2015-12-24 US disclosed
US-20120021061-A1 MEDICAL AND NUTRITIONAL FORMULATIONS COMVITA NEW ZEALAND LIMITED (NZ) 2012-01-26 US disclosed
EP-1126838-A4 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-02-16 EP disclosed
EP-1126838-A1 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2001-08-29 EP disclosed
WO-2000025776-A1 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-05-11 WO disclosed
JP-H02215720-A NOVEL MEDICINE FOR FEMALE CONTRACEPTION VIA INTRAUTERINE ROUTE AND ITS USE FOR TREATMENT THEREOF ZIPPER JAIME 1990-08-28 JP disclosed
US-4636516-A ANTIINFLAMMATORY, ANTIARTHRITIC, ANTIRHEUMATIC, ANTIPYRETIC, ANALGESIC YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1987-01-13 US disclosed
US-3973024-A Analgesic and anti-inflammatory anilino-phenylacetic acid-(2,3 or 4 pyridyl)-methyl esters and derivatives CIBA-GEIGY CORPORATION (US) 1976-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120021061-A1 MEDICAL AND NUTRITIONAL FORMULATIONS FABP6, NNT, IAPP PTGS2 1188/4885PTGS1 909/4885CXCL8 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.